616.234.5000

Publications

Moore Laboratory

Selected Publications

Tran Nguyen AP, Daniel G, Valdés P, Islam MS, Schneider BL, Moore DJ. 2017. G2019S LRRK2 enhances the neuronal transmission of Tau in the mouse brain. Hum Mol Genet.        Article

Williams ET, Chen X, Moore DJ. In press. VPS35, the retromer complex and Parkinson’s disease. J Parkinsons Dis 7(2):219–233.       Article

Islam MS, Moore DJ. 2017. Mechanisms of LRRK2-dependent neurodegeneration: Role of enzymatic activity and protein aggregation. Biochem Soc Trans 45(1):163–172.      PubMed

Zheng L, Bernard-Marisassal N, Moullan N, D’Amico D, Auwerx J, Moore DJ, Knott G, Aebischer P, Schneider BL. 2017. Parkin functionally interacts with PGC-1a to preserve mitochondria and protect dopaminergic neurons. Hum Mol Genet 26(3):582–598.      Article

Islam MS, Nolte H, Jacob W, Ziegler AB, Pütz S, Grosjean T, Szczepanowska K, Trifunovic A, Braun T, Heumann H, Heumann R, Hovemann B, Moore DJ, Krüger M. 2016. Human R1441C LRRK2 regulates the synaptic vesicle preteome and phosphoproteome in a Drosophila model of Parkinson’s disease. Hum Mol Genet 25(24)5356–5382.        Article

Nucifora Jr FC, Nucifora LG, Ng CH, Arbez N, Guo Y, Roby E, Shani V, Engelender S, Wei D, Wang XF, Li T, Moore DJ, Pletnikova O, Troncoso JC, Sawa A, Dawson TM, Smith W, Lim KL, Ross CA. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 7:11792.      Article

Klionsky DJ…Moore DJ…Zughaier SM. 2016. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12(1):1–222.     Article

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ. 2015. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 77:49–61      PubMed     Article

Daniel G, Musso A, Tsika E, Fiser A, Glauser L, Pletnikova O, Schneider BL, Moore DJ. 2014. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson’s disease occurs independent of ATP13A2 (PARK9). Neurobiol Dis 73C:229–243      PubMed     Article

Dusonchet J, Li H, Guillily M, Liu M, Stafa K, Derada Troletti C, Boon JY, Saha S, Glauser L, Mamais A, Citro A, Youmans KL, Liu L, Schneider BL, Aebischer P, Yue Z, Bandopadhyay R, Glicksman MA, Moore DJ, Collins JJ, Wolozin B. 2014. A Parkinson’s disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum Mol Genet 23(18):4887-4905.      PubMed

Daniel G, Moore DJ. Modeling LRRK2 pathobiology in Parkinson’s disease: From yeast to rodents. In: Geyer M, Ellenbroek B, Marsden C, editors. Current Topics in Behavioral Neuroscience: Springer Berlin Heidelberg; c2014.     PubMed

Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ. 2014. Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopamineragenic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis 71 C:345-358.     PubMed     Article

Tsika E, Glauser L, Moser R, Fiser A, Daniel G, Sheerin UM, Lees A, Troncoso JC, Lewis PA, Bandopadhyay R, Schneider BL, Moore DJ. 2014. Parkinson’s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet 23(17):4621-4638.     PubMed

Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A, Biskup S, Xiong Y, Bandopadhyay R, Dawson VL, Dawson TM, Moore DJ. 2014. Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet 23(8):2055-2077.     PubMed

Tsika E, Moore DJ. 2013. Contribution of GTPase activity to LRRK2-associated Parkinson’s disease. Small GTPases 4(3):164-170.     PubMed

Biosa A, Trancikova A, Civiero L, Glauser L, Bubacco L, Greggio E, Moore DJ. 2013. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson’s disease-associated LRRK2. Hum Mol Genet 22(6):1140-1156.     PubMed

Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, Glauser L, West AB, Bandopadhyay R, Moore DJ. 2012. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One 7(10): e47784.     PubMed

Podhajska A, Musso A, Trancikova A, Stafa K, Moser R, Glauser L, Sonnay S, Moore DJ. 2012. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. PLoS One 7(6): e39942.     PubMed

Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D, Troncoso JC, Lee MK, Dawson TM, Dawson VL, Moore DJ. 2012. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21(11):2420-2431.     PubMed

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ. 2012. GTPase activity and neuronal toxicity of Parkinson’s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 8(2):e1002527.     PubMed

Ramonet D, Podhajska A, Stafa K, Sonnay S, Trancikova A, Tsika E, Pletnikova O, Troncoso JC, Glauser L, Moore DJ. 2012. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet 15(21):1725-1743.     PubMed

Glauser L, Sonnay S, Stafa K, Moore DJ. 2011. Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. J Neurochem 118(4):636-645.     PubMed

Ramonet D, Daher JPL, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ. 2011. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6(4):e18568.     PubMed

Dusonchet J, Kochubey O, Stafa K, Young SM, Zufferey R, Moore DJ, Schneider BL, Aebischer P. 2011. A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J Neurosci 3(3):907-912.     PubMed

Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, Dawson VL, Dawson TM, Moore DJ. 2010. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6(4):e1000902.     PubMed

Daher JPL, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, Beal MF, Thomas B, Dawson VL, Dawson TM, Moore DJ. 2009. Conditional transgenic mice expressing C-terminally truncated human a-synuclein (aSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegen 4:34.     PubMed